Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase III Randomized, Placebo Controlled Study of Pembrolizumab (MK 3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
NCT Number:
NCT03914612
Phase:
III
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Other Female Genital
Study Objectives:
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin, works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.
Study Documents
(MUSC NetID required for document access)